search
Back to results

Mediterranean Diet- and Psychological Well-being Theory-based Intervention to Reverse Metabolic Syndrome in Chile (CHILEMED)

Primary Purpose

Metabolic Syndrome

Status
Enrolling by invitation
Phase
Not Applicable
Locations
Chile
Study Type
Interventional
Intervention
Low fat diet
Mediterranean diet
Mediterranean diet plus psychological well-being support
Sponsored by
Pontificia Universidad Catolica de Chile
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metabolic Syndrome focused on measuring Metabolic syndrome, Mediterranean diet, Psychological well-being

Eligibility Criteria

25 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Adult men or women 25-70 years-old with existing metabolic syndrome defined as the presence of at least three of the following criteria: (i) abdominal obesity (waist circumference >90 cm in men or >80 cm in women), (ii) low HDL-cholesterol (<40 mg/dl in men or <50 mg/dl in women) or under HDL increasing drugs, (iii) high triglycerides (TG) (≥ 150 mg/dl) or under TG lowering drugs, (iv) high blood hypertension (blood pressure ≥ 130/85 mmHg) or under treatment, and (v) high blood glucose (fasting plasma glucose concentration ≥ 100 mg/dl) or under treatment.

Exclusion Criteria:

  • Absence of written informed consent
  • Inability/low chance of adherence to diets or attend scheduled visits
  • Allergy or intolerance to foods included in either interventional diets
  • Recent (<12 months) participation in weight loss program
  • Obesity with BMI >35 kg/m2 or due to endocrine diseases, with exception of treated hypothyroidism
  • Type 1 diabetes, unstable type 2 diabetes
  • Uncontrolled high blood pressure
  • Previous clinical atherosclerotic cardiovascular disease
  • Use of medications such as weight loss drugs, oral corticoids, immunosuppressants or cytotoxic agents
  • Advanced chronic liver disease
  • Previous organ transplantation
  • History of HIV-positive status or AIDS
  • History of inflammatory bowel disease or major gastrointestinal surgery (bariatric surgery, bowel resection)
  • Active psychiatric conditions: eating disorders, severe depression, bipolar disorder, schizophrenia
  • Short (<2 years) life expectancy
  • Current or previous (within the last year) participation in other clinical trials with dietary or drug interventions
  • Institutionalized subjects
  • Additional conditions that may limit adherence to the study

Sites / Locations

  • Pontificia Universidad Católica de Chile

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

Low fat diet

Mediterranean diet alone

Mediterranean diet plus psychological well-being support

Arm Description

The low fat diet group will be counseled to consume a dietary pattern with fat restriction including food intake based in the pre-specified nutritional criteria.

The Mediterranean group will receive indications to consume a locally adapted and feasible dietary pattern including characteristic Mediterranean foods based on Chilean food availability.

The Mediterranean diet + well-being intervention group will be subject to intake a locally adapted and feasible pattern of Mediterranean foods available in Chile in combination with a psychological well-being theory-based intervention.

Outcomes

Primary Outcome Measures

Metabolic syndrome
Metabolic syndrome is diagnosed when three out of five criteria from the NCEP ATPIII definition are present. The nutritional interventions will determine metabolic syndrome reversal when participants exhibit from 0 to 2 diagnostic criteria at the end of the study.

Secondary Outcome Measures

Mediterranean Dietary adherence
Diet adherence to this food intake pattern will be assessed by the Chilean Mediterranean dietary index. Change in adherence to this diet will be evaluated as modification in the score (ranging from 0 to 14 points) during the interventions. Higher scores mean a better outcome.
Insulin Resistance
Insulin resistance will be assessed through the HOMA-IR index obtained by measuring fasting glucose (mg/dL) and fasting insulin (uU/mL).
Glucose homeostasis
Overall glucose homeostasis will be evaluated by measuring glycated hemoglobin (HbA1c)
Lipid profile
Fasting triglycerides, total cholesterol, and HDL-cholesterol (all expressed as mg/dL) will be assessed to categorize lipid changes.
High sensitivity C-reactive protein
High sensitivity C-reactive protein will be determined as pro-inflammatory and prognostic biomarker.
Plasma antioxidant capacity
Ferric reducing ability of plasma (FRAP) in fasting plasma samples of participants will be used to assess total plasma antioxidant activity.
Lipid peroxidation
Oxidized low-density lipoprotein (oxLDL) will be measured as lipid peroxidation biomarker
Serum protein oxidation
Advanced oxidation protein products (AOPP) will be measured in serum samples as a biomarker of oxidative stress in proteins.
Body mass index (BMI)
BMI will be calculated using weight and height in order to define the nutritional status of the patients
Abdominal obesity
Abdominal/central obesity will be evaluated by measuring waist circumference
Blood pressure control
Systolic/diastolic blood pressures will be assessed.
Type 2 diabetes mellitus
Type 2 diabetes mellitus will be assessed based on ADA definitions, including fasting glycemia ≥ 126 mg/dl, 2-h glycemia ≥ 200 mg/dl after glucose challenge, HbA1C ≥6.5%, or patient with hyperglycemic symptoms and random glycemia ≥ 200 mg/dl.
Psychological well-being
The Ryff's multidimensional questionnaire/scale will be used to assess psychological well-being levels. Change in well-being will be evaluated as modification in the overall scale score (from 29 to 174 points) during the interventions. Higher scores means a better psychological well-being outcome.
Positive mental health
Mental Health Continuum-short form questionnaire will be applied to assess positive emotional, psychological, and social well-being
Emotional affectivity
Positive and Negative Affect Schedule survey will evaluate emotional affectivity
Life, quality of
Quality of life will be assessed using the health-related quality of life (HRQoL) multidimensional SF-36 questionnaire. This questionnaire evaluates 8 dimensions using specific scales, each one ranging from 0 to 100 points. Higher scores indicate better quality of life.
Psychological illness
Psychological illness will be assessed using the DASS-21 self-reported questionnaire. This questionnaire includes depression, anxiety and stress scales, each one ranging from 0 to 21 points. Higher scores indicate worse psychological illness.

Full Information

First Posted
September 12, 2020
Last Updated
August 3, 2022
Sponsor
Pontificia Universidad Catolica de Chile
search

1. Study Identification

Unique Protocol Identification Number
NCT05454904
Brief Title
Mediterranean Diet- and Psychological Well-being Theory-based Intervention to Reverse Metabolic Syndrome in Chile
Acronym
CHILEMED
Official Title
Design, Implementation, and Prospective Evaluation of a Mediterranean Diet- and Psychological Well-being Theory-based Intervention to Reverse Metabolic Syndrome, a Highly Prevalent Chronic Disease Risk Condition in Chile
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Enrolling by invitation
Study Start Date
March 15, 2021 (Actual)
Primary Completion Date
March 31, 2024 (Anticipated)
Study Completion Date
March 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pontificia Universidad Catolica de Chile

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Promotion of MedDiet adherence and psychological well-being in Chile offers a great potential to confront our ongoing epidemiological transition to increased risk factors and non-communicable chronic diseases. The main aims of this clinical trial are to design, implement, and evaluate the impact of a MedDiet- and psychological well-being-based intervention on reversal rate of MetS -compared to a control low fat diet- in Chilean adult population.
Detailed Description
BACKGROUND: Non-communicable diseases (NCDs) are currently major causes of morbidity and mortality as well as economic healthcare burden worldwide, including Chile. Predisposing psychosocial as well as lifestyle risk factors -such as an unhealthy diet- have driven this global increase in NCDs. Overall, the ongoing epidemiological transition and current health situation in our country calls out for an urgent need to further evaluation of disease-related psychosocial factors and diet as well as definition of evidence-based feasible and effective nutritional interventions in the Chilean population. In addition, dietary interventions may be more easily incorporated and followed if provided and supported by theory-based and contextually grounded psychological approaches within a comprehensive positive psychosocial framework. Currently, the Mediterranean diet (MedDiet) is one of the healthiest dietary patterns based on observational studies in developed countries showing that adherence to this food intake pattern associates with lower prevalence/incidence of several NCDs, including metabolic syndrome (MetS), and reduced total mortality. Far fewer interventional studies -essentially performed in Europe and some of them questioned due to methodological issues and others with inconsistent findings- have reported favorable effects of MedDiets on clinical outcomes. Thus, impact of MedDiet on high-risk conditions (i.e., MetS) and clinical end-points in populations outside the Mediterranean Basin remains unknown. Thus, additional interventional studies about this dietary pattern on disease outcomes in more diverse populations, including our country, are needed. A Mediterranean lifestyle goes beyond mere food intake: it includes promotion of psychosocial resources, community life as well as cultural traditions. Indeed, Mediterranean lifestyle is a real way of life that integrally promotes physical, mental, and social well-being. However, psychological well-being (PWB) is much more than absence mental disorders. From a positive framework, PWB encompasses emotional/subjective well-being together with effective psychological functioning within a favorable social context and has been associated with healthy behaviors, positive health outcomes, and longevity. Promotion of PWB is in fact an emerging goal in healthcare, shifting the focus from treating/preventing mental disease to enhancing positive aspects of mental health. If PWB interventions are feasible and effective in boosting adherence to health behaviors, they may become a cost-effective tool to improve biomarker, functional and clinical outcomes related to NCDs. Based in this latter broad and positive psychosocial paradigm, promotion of PWB may facilitate acquisition and routine practice of healthy lifestyles, such as MedDiet, decreasing risk of NCDs. However, to our knowledge, PWB theory-based interventions have not been tested as a new approach to increase MedDiet adherence. Based on the multi-construct model of this theory, which is consistent with a Mediterranean lifestyle, a comprehensive PWB intervention program may increase adherence to MedDiet and -in turn- enhance its impact on chronic disease risk conditions such as MetS. Remarkably, Central Chile has a Mediterranean-like environment and food production comparable to those present in Mediterranean countries. Chilean culinary traditions also use ingredients and cooking techniques similar to Mediterranean cuisine. Thus, promotion of MedDiet adherence in Chile offers a great potential to confront our ongoing epidemiological transition to increased risk factors and NCDs. Despite our geography, food production, culinary traditions, and potential health benefits, very few studies have evaluated the potential impact of MedDiet patterns on health and/or disease in Chilean subjects. Furthermore, these studies exhibit important methodological limitations, such as only cross sectional observational analysis or small sample sizes, no control comparators for interventions, lack of theory-based behavior change advice, and use of intermediate biomarkers rather than clinical end-points. Better designed intervention studies using a locally tailored MedDiet index, feasible dietary prescription, novel PWB advice strategies as well as comprehensive outcome evaluation are required to further support and more extensively implement this dietary pattern and its associated positive psychosocial features for NCD prevention and treatment in our population. GUIDING HYPOTHESES. A psychological well-being theory-based behavioral support increases long-term MedDiet adherence and this nutritional intervention combined with promotion of psychological well-being is more effective at reversing MetS in Chilean subjects (primary outcome) and improving additional relevant biomarkers, clinical conditions, and well-being (secondary outcomes) compared to individuals following a low fat dietary pattern alone. OVERALL AIMS: 1. To design a PWB intervention as well as to refine a MedDiet pattern adapted and contextualized to Chilean subjects; 2. To determine if a customized psychological well-being intervention facilitates initiation and long-term adherence to a MedDiet dietary pattern in Chilean subjects with MetS; 3. To demonstrate that a locally adapted MedDiet pattern in association with a psychological well-being intervention -versus a low fat diet alone- increases the reversal rate of MetS; and 4. To establish whether this dietary approach with or without a psychological intervention improves traditional and novel disease biomarkers as well as non-alcoholic fatty liver disease and psychological well-being -compared to a control low fat diet- in Chilean subjects with MetS. METHODOLOGY. Overall, this proposal will design and implement a PWB theory-based behavior change strategy to increase MedDiet adherence and perform a clinical MedDiet intervention as main experimental research approaches. A tailored contextualized PWB intervention will be designed using information derived from focus group-based qualitative research. Then, a parallel-group randomized controlled clinical trial will be developed to determine the impact of MedDiet- and psychological well-being theory-based nutritional intervention on MetS (primary end-point), disease-associated biomarkers, fatty liver disease, depression, quality of life, and psychological well-being (secondary outcomes). Appropriate study protocols, anthropometric, questionnaire-based, biochemical, imaging, and clinical follow-up evaluations as well as proper statistical approaches will be implemented and applied in the RCT study. SIGNIFICANCE AND IMPLICATIONS: If the main findings turn out as expected (psychological well-being intervention facilitates adherence to MedDiet and this combined intervention reduces MetS and improves related-secondary clinical and psychosocial outcomes), this research proposal will provide further evidence on the beneficial health effects of the MedDiet beyond the Mediterranean basin, particularly in our country. Based on this locally generated evidence, MedDiet associated with promotion of positive psychosocial resources may be more compellingly applied to promote physical health and well-being as well as to prevent and treat NCD at individual and population levels in Chile.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome
Keywords
Metabolic syndrome, Mediterranean diet, Psychological well-being

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Three parallel-group randomized controlled clinical trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
339 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Low fat diet
Arm Type
Active Comparator
Arm Description
The low fat diet group will be counseled to consume a dietary pattern with fat restriction including food intake based in the pre-specified nutritional criteria.
Arm Title
Mediterranean diet alone
Arm Type
Active Comparator
Arm Description
The Mediterranean group will receive indications to consume a locally adapted and feasible dietary pattern including characteristic Mediterranean foods based on Chilean food availability.
Arm Title
Mediterranean diet plus psychological well-being support
Arm Type
Active Comparator
Arm Description
The Mediterranean diet + well-being intervention group will be subject to intake a locally adapted and feasible pattern of Mediterranean foods available in Chile in combination with a psychological well-being theory-based intervention.
Intervention Type
Behavioral
Intervention Name(s)
Low fat diet
Intervention Description
The low fat diet group will be counseled to consume a dietary pattern with fat restriction including food intake based in the following criteria: 1) <3 teaspoons/day of olive or Canola oil and <3 units/week of avocado, 2) removal of visible fat from meats before cooking or from cooked dishes before intake, 3) ≤1 serving per week fat-rich meats, hamburger, commercial ground meat, sausage, cured ham, bacon and salami, 4) daily consumption of low fat dairy products, 5) ≤1 serving/week of butter, margarine, lard, mayonnaise, milk cream, or milk- based ice cream, 6) ≤1 time/week intake of fatty fish or seafood, 7) ≤1 serving per week of commercial sweets or industrial bakery products (not homemade), and 8) ≤1 time/week consumption of nuts (including peanuts), potato chips, French fries, or commercial snacks. This intervention arm will be supplemented with powdered low fat milk (3 kgs/month) for daily use.
Intervention Type
Behavioral
Intervention Name(s)
Mediterranean diet
Intervention Description
The Mediterranean diet group will receive dietary recommendations as follows: 1) use of olive oil (>3 teaspoons/day), 2) Canola oil as second fat source for cooking and dressing or >3 units/week of avocado; 3) ≥3 daily servings of vegetables (at least one of them as fresh vegetables in a salad), 4) ≥2 daily servings of fresh fruits; 5) ≥2 weekly servings of legumes; 6) >2 weekly servings of fresh, canned or frozen fish (at least one serving of oily fish)/seafood; 7) ≥2 weekly servings of nuts/seeds; 8) 4-8 servings/week of white meats (poultry or turkey without skin) instead of 9) fatty or processed meats (<1 serving/week), 10) ≥2 daily servings of whole grains, 11) ≥1 daily/serving of low fat and fermented dairy products, 12) <1 daily/serving of whole fat dairy products, 13) ≤1 daily/serving of sugary snacks, drinks or juices and <4 teaspoons/daily of sugar, and 14) moderate (1-2 drinks/day) wine consumption with meals.
Intervention Type
Behavioral
Intervention Name(s)
Mediterranean diet plus psychological well-being support
Intervention Description
This group will be subjected to the same Mediterranean diet pattern indicated previously as well as to a psychological well-being intervention that will include a variety of components/activities, embracing values, purpose, self-acceptance, character strengths, emotional regulation, dealing with negativity, goal-setting, mindfulness, savoring, gratitude, autonomy, relationships, social interactions, and prosocial behavior.
Primary Outcome Measure Information:
Title
Metabolic syndrome
Description
Metabolic syndrome is diagnosed when three out of five criteria from the NCEP ATPIII definition are present. The nutritional interventions will determine metabolic syndrome reversal when participants exhibit from 0 to 2 diagnostic criteria at the end of the study.
Time Frame
Month 12
Secondary Outcome Measure Information:
Title
Mediterranean Dietary adherence
Description
Diet adherence to this food intake pattern will be assessed by the Chilean Mediterranean dietary index. Change in adherence to this diet will be evaluated as modification in the score (ranging from 0 to 14 points) during the interventions. Higher scores mean a better outcome.
Time Frame
Month 6 and 12
Title
Insulin Resistance
Description
Insulin resistance will be assessed through the HOMA-IR index obtained by measuring fasting glucose (mg/dL) and fasting insulin (uU/mL).
Time Frame
Month 6 and 12
Title
Glucose homeostasis
Description
Overall glucose homeostasis will be evaluated by measuring glycated hemoglobin (HbA1c)
Time Frame
Month 6 and 12
Title
Lipid profile
Description
Fasting triglycerides, total cholesterol, and HDL-cholesterol (all expressed as mg/dL) will be assessed to categorize lipid changes.
Time Frame
Month 6 and 12
Title
High sensitivity C-reactive protein
Description
High sensitivity C-reactive protein will be determined as pro-inflammatory and prognostic biomarker.
Time Frame
Month 6 and 12
Title
Plasma antioxidant capacity
Description
Ferric reducing ability of plasma (FRAP) in fasting plasma samples of participants will be used to assess total plasma antioxidant activity.
Time Frame
Month 6 and 12
Title
Lipid peroxidation
Description
Oxidized low-density lipoprotein (oxLDL) will be measured as lipid peroxidation biomarker
Time Frame
Month 6 and 12
Title
Serum protein oxidation
Description
Advanced oxidation protein products (AOPP) will be measured in serum samples as a biomarker of oxidative stress in proteins.
Time Frame
Month 6 and 12
Title
Body mass index (BMI)
Description
BMI will be calculated using weight and height in order to define the nutritional status of the patients
Time Frame
Month 6 and 12
Title
Abdominal obesity
Description
Abdominal/central obesity will be evaluated by measuring waist circumference
Time Frame
Month 6 and 12
Title
Blood pressure control
Description
Systolic/diastolic blood pressures will be assessed.
Time Frame
Month 6 and 12
Title
Type 2 diabetes mellitus
Description
Type 2 diabetes mellitus will be assessed based on ADA definitions, including fasting glycemia ≥ 126 mg/dl, 2-h glycemia ≥ 200 mg/dl after glucose challenge, HbA1C ≥6.5%, or patient with hyperglycemic symptoms and random glycemia ≥ 200 mg/dl.
Time Frame
Month 6 and 12
Title
Psychological well-being
Description
The Ryff's multidimensional questionnaire/scale will be used to assess psychological well-being levels. Change in well-being will be evaluated as modification in the overall scale score (from 29 to 174 points) during the interventions. Higher scores means a better psychological well-being outcome.
Time Frame
Month 6 and 12
Title
Positive mental health
Description
Mental Health Continuum-short form questionnaire will be applied to assess positive emotional, psychological, and social well-being
Time Frame
Month 6 and 12
Title
Emotional affectivity
Description
Positive and Negative Affect Schedule survey will evaluate emotional affectivity
Time Frame
Month 6 and 12
Title
Life, quality of
Description
Quality of life will be assessed using the health-related quality of life (HRQoL) multidimensional SF-36 questionnaire. This questionnaire evaluates 8 dimensions using specific scales, each one ranging from 0 to 100 points. Higher scores indicate better quality of life.
Time Frame
Month 6 and 12
Title
Psychological illness
Description
Psychological illness will be assessed using the DASS-21 self-reported questionnaire. This questionnaire includes depression, anxiety and stress scales, each one ranging from 0 to 21 points. Higher scores indicate worse psychological illness.
Time Frame
Month 6 and 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult men or women 25-70 years-old with existing metabolic syndrome defined as the presence of at least three of the following criteria: (i) abdominal obesity (waist circumference >90 cm in men or >80 cm in women), (ii) low HDL-cholesterol (<40 mg/dl in men or <50 mg/dl in women) or under HDL increasing drugs, (iii) high triglycerides (TG) (≥ 150 mg/dl) or under TG lowering drugs, (iv) high blood hypertension (blood pressure ≥ 130/85 mmHg) or under treatment, and (v) high blood glucose (fasting plasma glucose concentration ≥ 100 mg/dl) or under treatment. Exclusion Criteria: Absence of written informed consent Inability/low chance of adherence to diets or attend scheduled visits Allergy or intolerance to foods included in either interventional diets Recent (<12 months) participation in weight loss program Obesity with BMI >35 kg/m2 or due to endocrine diseases, with exception of treated hypothyroidism Type 1 diabetes, unstable type 2 diabetes Uncontrolled high blood pressure Previous clinical atherosclerotic cardiovascular disease Use of medications such as weight loss drugs, oral corticoids, immunosuppressants or cytotoxic agents Advanced chronic liver disease Previous organ transplantation History of HIV-positive status or AIDS History of inflammatory bowel disease or major gastrointestinal surgery (bariatric surgery, bowel resection) Active psychiatric conditions: eating disorders, severe depression, bipolar disorder, schizophrenia Short (<2 years) life expectancy Current or previous (within the last year) participation in other clinical trials with dietary or drug interventions Institutionalized subjects Additional conditions that may limit adherence to the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Attilio Rigotti
Organizational Affiliation
Professor
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pontificia Universidad Católica de Chile
City
Santiago
State/Province
Metropolitana
ZIP/Postal Code
8331150
Country
Chile

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
27905651
Citation
Dussaillant C, Echeverria G, Urquiaga I, Velasco N, Rigotti A. [Current evidence on health benefits of the mediterranean diet]. Rev Med Chil. 2016 Aug;144(8):1044-1052. doi: 10.4067/S0034-98872016000800012. Spanish.
Results Reference
background
PubMed Identifier
28393987
Citation
Echeverria G, Urquiaga I, Concha MJ, Dussaillant C, Villarroel L, Velasco N, Leighton F, Rigotti A. [Validation of self-applicable questionnaire for a Mediterranean dietary index in Chile]. Rev Med Chil. 2016 Dec;144(12):1531-1543. doi: 10.4067/S0034-98872016001200004. Spanish.
Results Reference
background
PubMed Identifier
28393974
Citation
Urquiaga I, Echeverria G, Dussaillant C, Rigotti A. [Origin, components and mechanisms of action of the Mediterranean diet]. Rev Med Chil. 2017 Jan;145(1):85-95. doi: 10.4067/S0034-98872017000100012. Spanish.
Results Reference
background
PubMed Identifier
28800091
Citation
Echeverria G, McGee EE, Urquiaga I, Jimenez P, D'Acuna S, Villarroel L, Velasco N, Leighton F, Rigotti A. Inverse Associations between a Locally Validated Mediterranean Diet Index, Overweight/Obesity, and Metabolic Syndrome in Chilean Adults. Nutrients. 2017 Aug 11;9(8):862. doi: 10.3390/nu9080862.
Results Reference
background
PubMed Identifier
30487560
Citation
Echeverria G, Dussaillant C, McGee EE, Mena C, Nitsche MP, Urquiaga I, Bitran M, Pedrals N, Rigotti A. Promoting and Implementing the Mediterranean Diet in the Southern Hemisphere: the Chilean Experience. Eur J Clin Nutr. 2019 Jul;72(Suppl 1):38-46. doi: 10.1038/s41430-018-0307-7.
Results Reference
background
PubMed Identifier
33207718
Citation
Echeverria G, Tiboni O, Berkowitz L, Pinto V, Samith B, von Schultzendorff A, Pedrals N, Bitran M, Ruini C, Ryff CD, Del Rio D, Rigotti A. Mediterranean Lifestyle to Promote Physical, Mental, and Environmental Health: The Case of Chile. Int J Environ Res Public Health. 2020 Nov 16;17(22):8482. doi: 10.3390/ijerph17228482.
Results Reference
background
PubMed Identifier
34249989
Citation
Figueroa C, Echeverria G, Villarreal G, Martinez X, Ferreccio C, Rigotti A. Introducing Plant-Based Mediterranean Diet as a Lifestyle Medicine Approach in Latin America: Opportunities Within the Chilean Context. Front Nutr. 2021 Jun 25;8:680452. doi: 10.3389/fnut.2021.680452. eCollection 2021.
Results Reference
background

Learn more about this trial

Mediterranean Diet- and Psychological Well-being Theory-based Intervention to Reverse Metabolic Syndrome in Chile

We'll reach out to this number within 24 hrs